A suite of bioassays to evaluate CREB inhibitors

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

The cyclic-AMP response element binding protein (CREB) is an important nuclear transcription factor and has been shown to be overexpressed and/or over-activated in many different cancer types, suggesting that targeting CREB is a novel approach for developing cancer therapies. Our lab discovered the first cell-permeable small molecule inhibitor of CREB, from which we further developed a potent CREB inhibitor with in vivo anti-cancer activity. In this article, we detailed our biochemical and cell-based bioassays to assess different small molecule CREB inhibitors.

Original languageEnglish (US)
Title of host publicationChemical and Synthetic Biology Approaches To Understand Cellular Functions - Part C
EditorsArun K. Shukla
PublisherAcademic Press Inc.
Pages169-184
Number of pages16
ISBN (Print)9780128191286
DOIs
StatePublished - 2020

Publication series

NameMethods in Enzymology
Volume633
ISSN (Print)0076-6879
ISSN (Electronic)1557-7988

Keywords

  • CREB
  • Inhibitor
  • Luciferase
  • Protein-protein interaction
  • Reporter
  • Transcription

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Fingerprint

Dive into the research topics of 'A suite of bioassays to evaluate CREB inhibitors'. Together they form a unique fingerprint.

Cite this